Handok, Actelion enter into licensing agreement

Published: 2008-10-10 06:51:00
Updated: 2008-10-10 06:51:00
Handok Pharm and Actelion Pharmaceuticals Korea announced on October 7 that they have entered into a licensing agreement for Actelion’s clazosentan, an intravenous endothelin receptor antagonist.

Under the agreement, the two companies will jointly collaborate the pivotal phase III study of cla...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.